Interestingly, a prediction model based on 21 plasma proteins was able to accurately distinguish individuals with AD and TREM2 genetic variants from non-TREM2 AD cases (AUC = 0.90), which was considerably more powerful than using the CSF p-tau/Aβ42/40 ratio (AUC = 0.63, p = 1.5 × 10−4). This evidence concerns the gene MAPT and Alzheimer disease.